Envoyer à un ami

Jardiance® (empagliflozin) significantly reduced the risk of progressive kidney disease ...

- 14 Juin 2016 modifié le 1 Janvier 1970

  • Jardiance® (empagliflozin) is the only SGLT2 inhibitor to demonstrate the potential to improve kidney outcomes on top of standard of care
  • New data from the landmark EMPA-REG OUTCOME® clinical trial published in The New England Journal of Medicine

(BUSINESS WIRE)-- New data showed Jardiance® (empagliflozin) reduced the risk for new-onset or worsening kidney disease by 39 percent versus placebo when added to standard of care in people with type 2 diabetes with established cardiovascular disease. Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today that the findings have been published in The New England Journal of Medicine and also presented at the American Diabetes Association (ADA) 76th Scientific Sessions® in New Orleans. ...

Source :